ReviewCurrent hypertension reports2004
Genes for left ventricular hypertrophy.
Review in Current hypertension reports, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- Angiotensin-converting enzyme gene deletion allele increases the risk of left ventricular hypertrophy: evidence from a meta-analysis.Molecular biology reports · 2012Pooled it
- Pooled it
- Parental history of myocardial infarction and risk of heart failure in male physicians.European journal of clinical investigation · 2008Trial
- Seven Deadly Sins in Hypertension Management: In-Depth Analysis of the Errors on a Journey from Riva-Rocci to Myocardial Fibrosis.Arquivos brasileiros de cardiologia · 2025Review
- Family History of Hypertension and Echocardiographic Left Ventricular Hypertrophy in Hypertensive Nigerians.Global health, epidemiology and genomics · 2024Article
- Left ventricular cardiac geometry and ambulatory blood pressure in children.Journal of clinical hypertension (Greenwich, Conn.) · 2019Article
- A combined linkage, microarray and exome analysis suggests MAP3K11 as a candidate gene for left ventricular hypertrophy.BMC medical genomics · 2018Article
- Prognostic Application of Thoracic Aortic Calcium Scoring for Adverse Clinical Outcome Risk in Elderly Patients with Left Ventricular Hypertrophy.Korean circulation journal · 2017Article
- Article
- Myocardial remodeling in hypertension.Journal of human hypertension · 2015Review
- Increased left ventricular mass as a predictor of sudden cardiac death: is it time to put it to the test?Circulation. Arrhythmia and electrophysiology · 2013Review
- Usefulness of desirable lifestyle factors to attenuate the risk of heart failure among offspring whose parents had myocardial infarction before age 55 years.The American journal of cardiology · 2012Article
- Potential Markers in Cardiac Hypertrophy?EJIFCC · 2012Article
- Genetic epidemiology of left ventricular hypertrophy.American journal of cardiovascular disease · 2012Article
- A follow-up study for left ventricular mass on chromosome 12p11 identifies potential candidate genes.BMC medical genetics · 2011Article
- Association between transforming growth factor beta1 polymorphisms and left ventricle hypertrophy in essential hypertensive subjects.Molecular and cellular biochemistry · 2010Article
- Genome-wide association of echocardiographic dimensions, brachial artery endothelial function and treadmill exercise responses in the Framingham Heart Study.BMC medical genetics · 2007Article
- Adiposity and cardiac dimensions among 9- to 18-year-old youth: the Québec Family Study.Journal of human hypertension · 2007Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
Left ventricular (LV) hypertrophy is very common, particularly among hypertensives. The presence of LV hypertrophy profoundly affects morbidity and mortality from cardiovascular diseases and stroke, and is now recognized as the most important predictor of chronic heart failure. Hypertension, obesity, and diabetes are important determinants of LV hypertrophy, but they fail to identify many individuals with the condition, suggesting that other factors, likely genetic in origin, play a role. Although much research has been undertaken to understand the causes of hypertrophy and the medical treatments that can lead to its regression, much remains unknown about its genetic basis. LV hypertrophy is considered a complex genetic disease, likely representing an interaction of several genes with the environment. The heritability of LV mass, measured as a quantitative trait, falls between 0.3 and 0.7 in different populations, suggesting it has a familial component. Genes encoding proteins involved in LV structure, as well as genes encoding cell signal transduction, hormones, growth factors, calcium homeostasis, substrate metabolism, and blood pressure are likely candidates for the development of common forms of LV hypertrophy. An overview of the pathophysiology of LV hypertrophy and dysfunction is provided, in addition to evidence of the genetic basis for LV hypertrophy in humans and animal models.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.